Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Beam Therapeutics Inc chart...

About the Company

beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team:  a community of fearless innovators  rigorous and honest in our research  listening with open minds  committed to each other

CEO

John M. Evans

Exchange

NASDAQ

Website

beamtx.com

$815M

Total Revenue

573

Employees

$3B

Market Capitalization

-9.91

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BEAM News

Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts

2d ago, source: Business Insider

Stay up to date on Beam Therapeutics analyst ratings. Get to Know Beam Therapeutics Better Beam Therapeutics Inc is a ...

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?

20h ago, source:

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK

3d ago, source:

Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA) application for BEAM-302 for the treatment of patients with ...

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

23d ago, source: MarketBeat on MSN

Beam Therapeutics Inc. (NASDAQ: BEAM) is a biotech company that specializes in developing precision gene therapies for ...

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

28d ago, source: Yahoo Finance

As you might know, Beam Therapeutics Inc. (NASDAQ:BEAM) just kicked off its latest annual results with some very strong numbers. The results were impressive, with revenues of US$378m exceeding ...

Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary

1mon ago, source: Benzinga.com

Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Bitcoin ...

Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK

3d ago, source: Nasdaq

(RTTNews) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA) application ...

Beam Therapeutics Inc

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...